Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
To help you effectively understand and manage the finances of your small business, we've tested the top accounting software based on customization, features, ease of use, value, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results